Abietic acid activates peroxisome proliferator-activated receptor-γ (PPARγ) in RAW264.7 macrophages and 3T3-L1 adipocytes to regulate gene expression involved in inflammation and lipid metabolism  by Takahashi, Nobuyuki et al.
Abietic acid activates peroxisome proliferator-activated receptor-Q
(PPARQ) in RAW264.7 macrophages and 3T3-L1 adipocytes to regulate
gene expression involved in in£ammation and lipid metabolism
Nobuyuki Takahashia;b, Teruo Kawadaa;b;, Tsuyoshi Gotoa, Chu-Sook Kimc, Aki Taimatsua,
Kahori Egawaa, Takayuki Yamamotoa, Mitsuo Jisakab;d, Koji Nishimurab;d,
Kazushige Yokotab;d, Rina Yuc, Tohru Fushikia
aLaboratory of Nutrition Chemistry, Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University,
Kyoto 606-8502, Japan
bProject for Obesity and Lipid Metabolism Regulation, Bio-oriented Research Advancement Institute (BRAIN), Tokyo 105-0001, Japan
cDepartment of Food Science and Nutrition, University of Ulsan, Ulsan 680-749, South Korea
dDepartment of Life Science and Biotechnology, Faculty of Life and Environmental Science, Shimane University, Shimane 690-8504, Japan
Received 10 February 2003; revised 16 June 2003; accepted 18 July 2003
First published online 6 August 2003
Edited by Robert Barouki
Abstract Abietic acid is one of the terpenoids, which are multi-
functional natural compounds. It has been reported that abietic
acid suppresses e¡ects on in£ammation. However, the mecha-
nism underlying the anti-in£ammatory e¡ects remains unclear.
The present work indicates that abietic acid suppresses the pro-
tein expression of tumor necrosis factor-K and cyclooxygenase
2, which are involved in in£ammation, in lipopolysaccharide-
stimulated macrophages. Moreover, this e¡ect resembles that
of thiazolidinedione, a synthetic peroxisome proliferator-acti-
vated receptor-Q (PPARQ) ligand. Indeed, abietic acid activates
PPARQ in luciferase reporter assays. The activity of abietic acid
induces PPARQ target gene expression in RAW264.7 macro-
phages and 3T3-L1 adipocytes. These data indicate that abietic
acid is a PPARQ ligand and that its anti-in£ammatory e¡ect is
partly due to the activation of PPARQ in stimulated macro-
phages. The present work suggests a novel possibility that
abietic acid, a naturally occurring compound, can be used not
only for anti-in£ammation but also for regulating lipid metab-
olism and atherosclerosis.
/ 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Terpenoids, which are present in many dietary and herbal
plants [1], exhibit many biological e¡ects: for example, anti-
tumor proliferation, antihypercholesterolemia and antidiabe-
tes [1^3]. Therefore, terpenoids have been regarded as valua-
ble medicinal and food components that control many cellular
functions and medical conditions in vivo.
Abietic acid, a diterpene, is a major component of the rosin
fraction of oleoresin synthesized by conifer species, such as
grand ¢r (Abies grandis) and lodgepole pine (Pinus contorta)
[4]. The chemical structure of abietic acid is shown in Fig. 1A.
It was reported that abietic acid has an anti-in£ammatory
e¡ect [5^7]. In lipopolysaccharide (LPS)-stimulated macro-
phages, abietic acid suppresses production of prostaglandin
E2 (PGE2) in vitro and in vivo [7]. However, the mechanism
underlying the anti-in£ammatory e¡ect of abietic acid has not
been clari¢ed.
The anti-in£ammatory e¡ect is regulated by many tran-
scriptional factors in vivo. Among the transcriptional factors,
peroxisome proliferator-activated receptor-Q (PPARQ), a mem-
ber of the nuclear receptor superfamily activated by ligands,
plays an important role in in£ammation [8,9]. The activation
of PPARQ signaling enhances macrophage di¡erentiation, in-
ducing the expression of fatty acid translocase (FAT)/CD36,
one of the cell’s ‘scavenger’ receptors for the atherogenic low-
density lipoprotein (LDL) [10]. Lipoprotein lipase (LPL) also
acts as a bridge, which enhances binding to the extracellular
matrix and uptake of both native and oxidized LDL by mac-
rophages. These molecules expressed in macrophages may ex-
hibit pro-atherogenic activities. However, thiazolidinedione
(TZD), a synthetic ligand for PPARQ, suppresses the produc-
tion of pro-in£ammatory cytokines including tumor necrosis
factor-K (TNF-K) and interleukin-6 (IL-6) in LPS- or phorbol
12-myristate-13-acetate-stimulated macrophages [11,12]. Re-
cent studies showed that, in addition to the anti-in£ammatory
e¡ect, TZD regulates expression of genes involved in lipid
metabolism in macrophages and suppresses their transforma-
tion into foam cells [11,13]. Therefore, regulation of PPARQ
by TZD in macrophages is indispensable not only for anti-
in£ammatory events but also for the transformation into
foam cells. On the other hand, TZD has been widely used
as an antidiabetic drug, which activates PPARQ resulting pro-
motion of adipocyte di¡erentiation ([14], review). TZD not
only stimulates glucose uptake into di¡erentiated adipocytes
but also induces production of adiponectin (an insulin sensi-
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tivity-promoting factor) and suppression of TNF-K (a insulin
resistance-inducing factor) through PPARQ activation in adi-
pocytes [15^17]. Thus, ligands for PPARQ such as TZD can
show multiple e¡ects including antidiabetes, anti-in£amma-
tion, and antiatherosclerosis.
In this study, we show similarity between abietic acid and
TZD in terms of suppressive activity for TNF-K and cyclo-
oxygenase 2 (COX2) induction at the protein level in LPS-
stimulated macrophages. Moreover, the results demonstrate
that abietic acid activates PPARQ in the GAL4 chimera sys-
tem. Indeed, abietic acid could induce the expression of PPARQ
target genes in RAW264.7 macrophages and 3T3-L1 adipo-
cytes. Moreover, the induction of PPARQ target gene expres-
sion depended on the expression of PPARQ and a nuclear
receptor coactivator, cAMP response element-binding protein
(CREB)-binding protein (CBP), in NIH3T3 ¢broblasts. These
data indicate that abietic acid is an activator of PPARQ and
the anti-in£ammatory e¡ect of abietic acid is, at least partly,
due to its activity as an activator of PPARQ. The results fur-
ther suggest that abietic acid is a valuable medicinal and food
component for use in control functions of macrophages and
adipocytes.
2. Materials and methods
2.1. Chemical reagents
T174 TZD, a speci¢c ligand for PPARQ [18], was kindly provided
by Tanabe Seiyaku (Osaka, Japan). Abietic acid and bisphenol A
diglycidyl ether (BADGE) were from Sigma (St. Louis, MO, USA)
or Tokyo Chemical Industry (Tokyo, Japan). These compounds were
diluted with dimethyl sulfoxide (DMSO) to prepare the stock solu-
tions (10^100 mM). All other chemicals were from Sigma or Nacalai
Tesque (Kyoto, Japan) and of guaranteed reagent grade or tissue
culture grade.
2.2. Cell culture
Monkey CV1 kidney cells, mouse 3T3-L1 preadipocytes, mouse
NIH3T3 ¢broblasts and mouse RAW264.7 macrophage were pur-
chased from American Type Culture Collection. They were cultured
in a maintenance medium (10% fetal bovine serum, 200 WM ascorbic
acid, 100 units/ml penicillin and 100 Wg/ml streptomycin in Dulbecco’s
modi¢ed Eagle’s medium) at 37‡C in 5% CO2/95% air under humidi-
¢ed condition. For adipocyte di¡erentiation, 3T3-L1 preadipocytes
were incubated in a di¡erentiation medium 2 days after they reached
con£uence, as described previously [19]. Cell viability was measured
using the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
assay as previously described [20].
2.3. Preparation of peritoneal macrophages
BALB/c male mice (Japan SLC, Hamamatsu, Japan) were injected
intraperitoneally with 3^4 ml of thioglycollate broth (Difco, Detroit,
MI, USA) (3%) 4 days before use. Peritoneal macrophages were pre-
pared as follows: lightly ether-anesthetized mice (n=4^6) were in-
jected intraperitoneally with 5 ml of sterilized phosphate-bu¡ered sa-
line. The peritoneal £uid was carefully aspirated to avoid hemorrhage.
After centrifugation at 200Ug for 10 min, the cell pellet was washed
twice with the maintenance medium. Cells were seeded at 1U106/ml in
the maintenance medium. After incubation for 2 h at 37‡C, non-ad-
herent cells were removed by extensive washing with the maintenance
medium. All animals received human care, as outlined in the Guide
for the Care and Use of Laboratory Animals (Kyoto University Ani-
mal Care Committee according to NIH 86-23; revised 1985).
2.4. Measurement of TNF-K and Western blot analysis of COX2
The concentration of TNF-K in culture supernatants was assayed
by enzyme-linked immunosorbent assay (ELISA). The assays were
conducted utilizing OptEIATM Mouse TNF-K set (Pharmingen, San
Diego, CA, USA). The samples were thawed, diluted properly in
assay diluents, and thoroughly mixed. Samples (triplicate) and stan-
dards (duplicate) were pipetted into the appropriate wells of the TNF-
K antibody-coated ELISA plate. Plates were sealed and incubated for
2 h at room temperature. After rinsing thoroughly, each well was
incubated for 1 h with 100 Wl of biotinylated mouse TNF-K mono-
clonal antibody and streptavidin^horseradish peroxidase conjugate.
Following another rinse, tetramethylbenzidine substrate solution was
placed in each well in the dark for 30 min. The absorbance of each
well was read at 450 nm on a microplate reader. Cytokines were
quantitated from standard curves using the SOFTmax curve-¢tting
program (Molecular Devices, Sunnyvale, CA, USA).
For Western blotting to analyze the expression of COX2, mouse
monoclonal COX2 antibody (Transduction Labs, Lexington, KY,
USA) was used. Western blotting was performed as previously de-
scribed [20].
2.5. Luciferase assays
Our luciferase assays were performed using an advanced highly
sensitive system with coexpression of coactivator CBP developed by
modifying the dual luciferase system (Promega, Madison, WI, USA),
as previously described [21]. Twenty-four hours after transfection of
both reporter and internal control plasmids, the transfected cells were
cultured in the medium containing each compound for another 24 h.
Luciferase assays were performed using the dual luciferase system
according to the manufacturer’s protocol.
2.6. RNA preparation and quanti¢cation of gene expressions
RNA samples of di¡erentiated 3T3-L1 were prepared using cells
cultured on 6-well tissue culture plates 8 days after di¡erentiation
induction. The cells were treated with the medium containing PPARQ
ligand for 48 h before RNA sample preparation. For analysis of gene
expression in RAW264.7 and NIH3T3, pSG5-mPPARQ, the expres-
sion vector for PPARQ, was transfected into RAW264.7 cultured on 6-
well plates with LipofectAMINE and Plus reagents (Invitrogen, San
Diego, CA, USA) as previously described [21]. Twenty-four hours
after the transfection, the transfected RAW264.7 and NIH3T3 cells
were treated for another 24 h with the experimental medium contain-
ing each sample compound. All the total RNA samples were prepared
from cells using the SV total RNA isolation system (Promega) ac-
cording to the manufacturer’s protocol.
Aliquots of total RNA were reverse-transcribed using M-MLV re-
verse transcriptase (Invitrogen) in a thermal cycler (Takara PCR
Thermal Cycler SP: Takara Shuzo, Kyoto, Japan) according to the
manufacturer’s instructions. To quantify mRNA expression, polymer-
ase chain reaction (PCR) was performed using a quantitative real-time
RT-PCR system (LightCycler System: Roche Diagnostics, Mann-
heim, Germany), as described previously [19,21]. All primer sets
used in this study were described previously [21]. To compare the
mRNA expression levels among samples, the copy numbers of each
transcript were divided by that of glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) showing a constant expression level.
2.7. Statistical analysis
The data are presented as meansUS.E.M. and were statistically
analyzed using the unpaired t-test or the Welch t-test when variances
were heterogeneous. Di¡erences were considered signi¢cant when P
was 6 0.05.
3. Results
3.1. Abietic acid and PPARQ ligand suppress expression of
TNF-K and COX2 in LPS-stimulated macrophages
To investigate the anti-in£ammatory e¡ect of abietic acid,
LPS-stimulated peritoneal macrophages were cultured in the
medium containing abietic acid. The addition of 50 WM
abietic acid suppressed LPS-induced production of TNF-K
(16.3% of the LPS-stimulated vehicle control) as shown in
Fig. 1B. This suppressive e¡ect of abietic acid on TNF-K
production was dose-dependent. Under the same experimental
conditions, 5 WM TZD, which regulates the expression of
macrophage di¡erentiation marker genes and in£ammation-
related genes via PPARQ activation, suppressed approximately
8.9% of the LPS-induced TNF-K production. Moreover, the
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protein expression of COX2, which is enhanced in LPS-stimu-
lated macrophages, was suppressed to 75.6% and 45.3% of the
LPS-stimulated vehicle control by 50 WM abietic acid and
5 WM TZD, respectively (Fig. 1C), although addition of a
lower concentration of abietic acid (25 WM) had no e¡ect.
These suppressive e¡ects of abietic acid on the protein expres-
sion of TNF-K and COX2 were con¢rmed at the mRNA level
by quanti¢cation of both mRNAs in stimulated peritoneal
macrophages by using quantitative RT-PCR (the addition of
50 WM abietic acid resulted in 65% and 80% of the vehicle
controls for the mRNA expressions of TNF-K and COX2,
respectively). These results suggest that abietic acid suppresses
the protein expression of both TNF-K and COX2 and that the
suppressive e¡ects of abietic acid and TZD are governed by
the same mechanism.
3.2. Abietic acid activates PPARQ as determined by luciferase
assays
We hypothesized that PPARQ is activated by abietic acid as
well as TZD, because of the similarity between abietic acid
and TZD in terms of their anti-in£ammatory e¡ects. Thus, we
carried out reporter assays for PPARQ ligands using abietic
acid. In the assays, abietic acid induced GAL4/PPARQ chi-
mera transactivation in a dose-dependent manner (Fig. 2A).
Using the GAL4/PPARQ chimera system, 30 WM abietic acid
induced activation 4.6-fold that of the vehicle control (Fig.
2A). The concentrations of abietic acid used in these assays
had no in£uence on cell viability (data not shown). Moreover,
in the GAL4/PPARQ chimera system, BADGE, a PPARQ an-
tagonist [22], suppressed luciferase activity of 10 WM of abietic
acid in a dose-dependent manner (Fig. 2B). The activity of
abietic acid in the presence of 1 WM BADGE was signi¢cantly
suppressed at 41% of the activity in the absence of BADGE.
It was shown that a binding site of this compound in the
ligand-binding domain (LBD) of PPARQ is the same as that
of TZD, as determined by competitive assays using 3H-labeled
TZD [22]. Therefore, these results indicate that abietic acid
activates PPARQ as determined by luciferase assays using the
GAL4/PPARQ chimera system and suggest that abietic acid,
as well as TZD, binds to the LBD of PPARQ.
Fig. 1. Abietic acid suppresses protein expression of pro-in£amma-
tory markers in LPS-stimulated macrophages. Structure of abietic
acid (A). Peritoneal macrophages were stimulated with 25 ng/ml
LPS and incubated for 24 h with abietic acid or TZD. B: Suppres-
sive e¡ects of abietic acid and TZD in LPS-induced TNF-K produc-
tion. The quanti¢cation of TNF-K released from LPS-stimulated
macrophages was performed using ELISA as described in Section 2.
The production level of LPS-induced TNF-K was set at 100%. The
values are meansUS.E.M. of four tests. *P6 0.05 compared with
LPS-induced TNF-K production. C: Suppressive e¡ects of abietic
acid and TZD in LPS-induced COX2 production. Equal amounts of
protein (15 Wg/lane) were loaded and electrophoresed on a 10% so-
dium dodecyl sulfate^polyacrylamide gel. After the protein separa-
tion, proteins were blotted onto a nitrocellulose membrane, and
then COX2 was detected using a chemiluminescent system (ECL).
The data are representative of three independent blots. The values
are meansUS.E.M. of three tests. *P6 0.05 compared with LPS-in-
duced COX2 expression.
Fig. 2. Abietic acid activates PPARQ as its ligand. A: Luciferase li-
gand assays using the PPARQ/GAL4 chimera system in CV1 cells.
pM-hPPARQ, p4xUASg-tk-luc, pCMX-CBP and pRL-CMV (an in-
ternal control) were transfected into CV1 cells and then, 24 h after
the transfection, the cells were treated with abietic acid at various
concentrations for 24 h. The activity of the vehicle control was set
at 100% and the relative luciferase activities are presented as fold in-
duction to that of the vehicle control. The values are means
US.E.M. of four tests. *P6 0.05 compared with the vehicle control.
B: Antagonization of activity of abietic acid as a PPARQ ligand by
BADGE. The same plasmids as used in ligand assays above were
transfected into CV1 cells and 24 h after the transfection 10 WM
abietic acid was added into the culture medium with or without
BADGE at various concentrations. After another 24 h, luciferase
assays were performed. The activity of 10 WM abietic acid without
BADGE was set at 100% and the relative luciferase activities are
presented as fold induction to that of the positive control. The val-
ues are meansUS.E.M. of four tests. *P6 0.05 compared with con-
trol without BADGE.
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3.3. Expression of PPARQ target genes is induced by abietic
acid in macrophages and adipocytes
To con¢rm whether abietic acid activated PPARQ in macro-
phages, we investigated the mRNA expression of PPARQ tar-
get genes in RAW264.7. In transiently PPARQ-expressing
RAW264.7 (the transfection e⁄ciencies were approximately
40% through all experiments), the expression of FAT/CD36
was induced 2.1-fold following the addition of 50 WM abietic
acid (closed columns in Fig. 3A), whereas that of LPL was
induced 4.9-fold (open columns in Fig. 3A). Mock control
cells showed no induction after addition of each compound
(data not shown). The expressions of FAT/CD36 and LPL are
controlled by PPARQ in macrophages [23,24]. Therefore, these
results suggest that abietic acid activates PPARQ to regulate
expression of PPARQ target genes in RAW264.7 macro-
phages.
Next, to examine the e¡ects of abietic acid on other cells,
we quanti¢ed the induction of PPARQ target gene expression
in 3T3-L1 adipocytes by abietic acid. In di¡erentiated 3T3-L1
adipocytes, 25 WM abietic acid induced 8.1-fold adipocyte
fatty acid-binding protein (aP2) expression 7 days after di¡er-
entiation induction (closed columns in Fig. 3B). In the case of
LPL, expression was induced 5.1-fold following the addition
of 25 WM abietic acid (open columns in Fig. 3B). Moreover,
these e¡ects of abietic acid were dose-dependent, because ad-
dition of 50 WM abietic acid resulted in 11.4- and 5.8-fold
increases in the expression levels of aP2 and LPL, respec-
tively. This suggests that abietic acid can induce expression
of aP2 and LPL via PPARQ activation in adipocytes.
3.4. The PPARQ target gene induction by abietic acid depends
on expression of PPARQ and coactivator
To elucidate the details of PPARQ target gene induction by
abietic acid, we used transiently PPARQ-expressing NIH3T3
¢broblasts (the e⁄ciency of transient transfection was approx-
imately 55% through all experiments), which di¡erentiate into
adipocyte-like cells in a PPARQ-ligand-dependent manner [25].
Addition of 25 WM abietic acid induced the expression of aP2
7.2-fold in the transiently PPARQ-expressing NIH3T3 as
shown in Fig. 4A. The e¡ect of abietic acid was dose-depen-
dent (50 WM abietic acid induced 32-fold expression). How-
ever, induction of aP2 expression was not observed in the
absence of PPARQ expression (Fig. 4A). Similar results were
obtained in the induction of LPL (data not shown). Mock
control cells showed no induction after addition of each com-
pound (data not shown). This strongly suggests that the reg-
ulation of PPARQ target gene expression by abietic acid is due
to activation of PPARQ. In addition to the dependence on
PPARQ expression, the induction of aP2 by abietic acid de-
pended on the expression of CBP, a coactivator for PPARQ.
The coexpression of CBP and PPARQ resulted in a 2.7-fold
induction of aP2 expression in the presence of 25 WM abietic
acid in comparison to the expression of only PPARQ, as
shown in Fig. 4B. Moreover, the enhanced aP2 induction
due to the coexpression of CBP and PPARQ was completely
inhibited by adenovirus oncoprotein E1A, which speci¢cally
inhibits CBP/p300 functions by its direct binding to the coac-
tivator proteins [26]. This coactivator-dependent activation of
abietic acid is the same as that of TZD as previously described
[19]. These results suggest that the activation of PPARQ by
abietic acid depends on the expression of a coactivator for
PPARQ, i.e. CBP.
4. Discussion
We showed that abietic acid suppresses the protein expres-
sion of TNF-K and COX2 in LPS-stimulated macrophages. It
was reported that abietic acid has anti-in£ammatory e¡ects
such as suppression of PGE2 production and lipoxygenase
activity [6,7]. The expression of COX2 is involved in the pro-
duction of prostaglandins including PGE2 in macrophages.
Therefore, it is suggested that the suppressive e¡ect of abietic
acid on PGE2 production is partly due to the suppression of
COX2 expression in macrophages.
Our present study shows that abietic acid activates PPARQ
in the GAL4 chimera system. This indicates that abietic acid
activates PPARQ as its ligand. The activity of abietic acid as a
PPARQ ligand is strongly supported by the competitive e¡ect
Fig. 3. Abietic acid induces expression of PPARQ target genes in
macrophages and di¡erentiated 3T3-L1 adipocytes. A: Transiently
PPARQ-expressing RAW264.7 cells were cultured on 6-well plates
and 24 h after transfection the stimulated cells were treated with or
without abietic acid for another 24 h. B: Di¡erentiated 3T3-L1 adi-
pocytes were treated with vehicle control (DMSO), 10 WM TZD, 25
and 50 WM abietic acid for 48 h 7 days after di¡erentiation induc-
tion. In both experiments, expression of mRNAs was estimated us-
ing LightCycler, a quantitative real-time RT-PCR (see Section 2).
The relative expression levels are presented as fold induction to that
of the vehicle control. All values are meansUS.E.M. of six tests.
*P6 0.05 compared with vehicle controls.
Fig. 4. Abietic acid regulates expression of PPARQ target genes in
NIH3T3 cells. A: NIH3T3 cells transfected with or without a PPARQ
expression vector (pSG5-PPARQ, 1.0 Wg/well) were cultured on 6-
well plates and 24 h after transfection TZD or abietic acid was
added to the culture medium and further incubated for 48 h. B:
CBP expression vector (pCMX-CBP, 1.0 Wg/well) with PPARQ ex-
pression vector (pSG5-PPARQ, 1.0 Wg/well) was transiently intro-
duced into NIH3T3 cells cultured on 6-well plates. Twenty-four
hours after the transfection, 25 or 50 WM abietic acid was added
into the medium and further incubated for another 24 h. Adenovi-
rus oncoprotein E1A expression vector (1.0 Wg/well)-transfected cells
were used as the negative control. In both experiments, the expres-
sion level of mRNAs was estimated using LightCycler and normal-
ized to the GAPDH expression level. The relative expression levels
are presented as fold induction to that of the vehicle control. All
values are meansUS.E.M. of six tests. *;**P6 0.05 compared with
vehicle controls and samples without CBP expression, respectively.
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of BADGE (an antagonist of PPARQ), which binds to PPARQ
LBD, as shown in Fig. 2B. Indeed, abietic acid could regulate
the expression of PPAR target genes (FAT/CD36 and LPL) in
PPARQ-expressing RAW264.7 macrophages (Fig. 3A). This
induction of PPARQ target genes by abietic acid depended
on PPARQ expression (Figs. 3A and 4A), suggesting that
abietic acid can regulate gene expression via PPARQ activa-
tion as its ligand in intact cells. It has been reported that
ligands of PPARQ such as TZD and 15-deoxy-v12;14-prosta-
glandin J2 suppress the expression and/or the production of
several in£ammatory cytokines including TNF-K, IL-6, IL-2
and PGE2 [9]. This suppressive activity of PPARQ is due to
inhibition of activities of NF-UB, STAT-1 and AP1 in in£am-
matory signaling [9]. This is partly because of the competition
in binding of CBP/p300 coactivators between PPARQ and
other transcriptional factors [27]. CBP/p300 is essential for
ligand-dependent activation of PPARQ as a coactivator [19].
The PPARQ activation by abietic acid depended on CBP ex-
pression as shown in Fig. 4B. Therefore, it is possible that the
anti-in£ammatory e¡ects of abietic acid are due to CBP-de-
pendent PPARQ activation in macrophages.
These results indicate that abietic acid is a functional acti-
vator of PPARs in intact cells. It has been reported that other
terpenoids including phytanic acid and isoprenols can activate
PPARs [20,27]. A common characteristic of such compounds
is their activity that regulates the expression of adipocyte dif-
ferentiation marker genes. Phytanic acid and farnesol increase
the expression levels of uncoupling protein-1 in primary cul-
tured brown adipocytes [28], and aP2/LPL in 3T3-L1 adipo-
cytes [21], respectively, via PPARQ activation. In our study,
abietic acid upregulated the expression of aP2 and LPL in
3T3-L1 adipocytes. Furthermore, in macrophages it was
shown that abietic acid increased the expression levels of
FAT/CD36 and LPL, which are associated with lipid metab-
olism and pathological processes such as atherosclerosis.
Therefore, there are possibilities that terpenoids including
abietic acid might be classi¢ed into a novel class of naturally
occurring PPAR ligands and that terpenoids might control
lipid metabolism in vivo via PPAR activation. In this sense,
it is interesting and might be valuable to analyze the relation-
ship between terpenoids in terms of their structures and abil-
ities to induce PPAR activation.
In conclusion, abietic acid suppresses expression of genes
involved in in£ammation such as TNF-K and COX2 in acti-
vated macrophages. This e¡ect is due to the ability of abietic
acid to activate PPARQ as its ligand. Abietic acid regulates the
expression of PPARQ target genes including aP2, LPL and
FAT/CD36 in 3T3-L1 adipocytes or RAW264.7 macrophages.
In this present work, we propose a possible mechanism of the
anti-in£ammatory e¡ect of abietic acid and its novel use for
transcriptional regulation for management of lipid metabo-
lism in adipocytes or macrophages.
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